Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Gain Therapeutics Inc (NASDAQ: GANX) closed the day trading at $1.91 down -4.02% from the previous closing price of $1.99. In other words, the price has decreased by -$4.02 from its previous closing price. On the day, 0.67 million shares were traded. GANX stock price reached its highest trading level at $2.0474 during the session, while it also had its lowest trading level at $1.865.
Ratios:
For a better understanding of GANX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.79 and its Current Ratio is at 1.79. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on March 07, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $12.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GANX now has a Market Capitalization of 68661824 and an Enterprise Value of 52759724.
Stock Price History:
The Beta on a monthly basis for GANX is 0.14, which has changed by 0.83653843 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, GANX has reached a high of $3.19, while it has fallen to a 52-week low of $0.95. The 50-Day Moving Average of the stock is 12.77%, while the 200-Day Moving Average is calculated to be 0.37%.
Shares Statistics:
Over the past 3-months, GANX traded about 322.84K shares per day on average, while over the past 10 days, GANX traded about 371710 shares per day. A total of 35.95M shares are outstanding, with a floating share count of 34.19M. Insiders hold about 4.90% of the company’s shares, while institutions hold 10.54% stake in the company. Shares short for GANX as of 1755216000 were 210923 with a Short Ratio of 0.65, compared to 1752537600 on 198826. Therefore, it implies a Short% of Shares Outstanding of 210923 and a Short% of Float of 0.61000003.
Earnings Estimates
At present, 3.0 analysts are actively evaluating the performance of Gain Therapeutics Inc (GANX) in the stock market.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.15 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.65 and -$0.69 for the fiscal current year, implying an average EPS of -$0.67. EPS for the following year is -$0.63, with 4.0 analysts recommending between -$0.35 and -$0.82.
